Date | Title | Description |
24.10.2024 | Vision Restored: The Breakthrough of the Prima Implant | In a world where darkness often reigns for those with vision loss, a flicker of hope has emerged. Science Corporation, a pioneer in brain-computer interface (BCI) technology, has unveiled a groundbreaking retinal implant called Prima. This ... |
23.10.2024 | Учёные из Science Corp. полностью вернули зрение пациентам с помощью импланта | Разработчики интерфейса мозг-компьютер (BCI) из Science Corporation объявили о предварительных результатах клинических испытаний своего имплантата сетчатки Prima. Он позволил полностью вернуть зрение пациентам.
1. Карманный процессор позвол... |
02.02.2024 | Pixium Vision annonce le rejet du plan de cession par le Tribunal et la conversion de la procédure de redressement judiciaire en liquidation judiciaire | Pixium Vision annonce le rejet du plan de cession par le Tribunal et la conversion de la procédure de redressement judiciaire en liquidation judiciaire
Paris, France, 2ème février 2024 – 14h00 CET – Pixium Vision SA (Euronext Growth Paris –... |
02.02.2024 | Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings | Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings
Paris, France, February 2, 2024 – 02:00 p.m. (CET) – Pixium Vision SA (Eur... |
17.01.2024 | Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings | Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings
Paris, France, January 17, 2024 – 7:00 am (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnem... |
17.01.2024 | Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire | Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire
Paris, France, 17 janvier 2024 – 07h00 CET – Pixium Vision SA (Euronext Growth Paris – FR001400JX97 ; Mnemo : ALPIX), so... |
26.10.2023 | Pixium Vision annonce ses résultats financiers du premier semestre 2023 et fait le point sur ses activités | Pixium Vision annonce ses résultats financiers du premier semestre 2023 et fait le point sur ses activités Événements ultérieurs à la période : obtention d’une avance en compte courant d’actionnaires de 3 millions d’euros de Bpifrance et So... |
26.10.2023 | Pixium Vision announces its financial results for H1 2023 and provides update | Pixium Vision announces its financial results for H1 2023 and provides update Post period event: Received shareholder loan of €3 million from BPIFrance and Sofinnova. Extension of the maturity of outstanding notes €1.25 million, Implemented... |
04.05.2023 | Startup Showcase: Pixium Vision – Developing Retinal Implant Systems to Restore Vision | Pixium Vision is a French-based company that is dedicated to developing innovative retinal implant systems for patients who have lost their vision. With the aim of restoring vision and improving the quality of life for patients, Pixium Visi... |
25.04.2023 | Pixium Vision announces the availability of its annual report for the financial year 2022 | /EIN News/ -- Pixium Vision announces the availability of its
annual report for the financial year 2022
Paris, April 25, 2023 – 7.00 p.m. CET - Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops ... |
03.04.2023 | Communication faisant suite à l’annonce de l’obtention du statut Breakthrough Device de la FDA pour le Système Prima dans le traitement de la DMLA sèche | /EIN News/ -- Communication faisant suite à l’annonce de l’obtention du statut Breakthrough Device de la FDA pour le Système Prima dans le traitement de la DMLA sèche Conversion de 160 ORNAN2022 par ESGO avec l'intention de procéder à une n... |
03.04.2023 | Communication following the announcement of FDA Breakthrough Device Designation for the Prima System in Dry AMD | /EIN News/ -- Communication following the announcement of FDA Breakthrough Device Designation for the Prima System in Dry AMD Conversion of 160 ORNAN2022 by ESGO with intention to pursue controlled trading of shares Cost reduction measures ... |
31.03.2023 | Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD | /EIN News/ -- Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD Pixium Vision to receive interactive communication with FDA through premarket review phase of Prima System and potential prioritized r... |
31.03.2023 | Pixium Vision annonce l’obtention du statut Breakthrough Device de la FDA pour le Système Prima dans le traitement de la DMLA sèche | /EIN News/ -- Pixium Vision annonce l’obtention du statut Breakthrough Device de la FDA pour le Système Prima dans le traitement de la DMLA sèche Pixium Vision et la FDA collaboreront étroitement pendant la phase d'examen préalable à la mis... |
10.03.2023 | Results of Extraordinary Shareholders Meeting held on March 8, 2023 | /EIN News/ -- Results of Extraordinary Shareholders Meeting held on March 8, 2023
Paris, France,March 10, 2023 – 19:00 CET – The Extraordinary Shareholders Meeting of Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a ... |
28.02.2023 | Extraordinary Shareholder Meeting of March 8, 2023: Notice of publication of the preparatory documents | /EIN News/ -- Extraordinary Shareholder Meeting of March 8, 2023: Notice of publication of the preparatory documents
Paris, France, February 28, 2023 – 19.00 am CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics... |
28.02.2023 | Assemblée Générale Extraordinaire du 8 mars 2023 : Modalités de mise à disposition des documents préparatoires | /EIN News/ -- Assemblée Générale Extraordinaire du 8 mars 2023 : Modalités de mise à disposition des documents préparatoires
Paris, le 28 février 2023 – 19h00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641 - Mnemo: ALPIX), soc... |
28.02.2023 | Extraordinary Shareholder Meeting of March 8, 2023: Notice of publication of the preparatory documents | Extraordinary Shareholder Meeting of March 8, 2023: Notice of publication of the preparatory documents
Paris, France, February 28, 2023 – 19.00 am CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that ... |
13.02.2023 | Pixium Vision announces termination of convertible note financing agreement with US-based healthcare investor ESGO | /EIN News/ -- Pixium Vision announces termination of convertible note financing agreement with US-based healthcare investor ESGO Termination will not trigger any penalty payments from Pixium Vision First tranche of financing worth €5.5 mill... |
13.02.2023 | Pixium Vision annonce la résiliation de l’accord de financement par voie d’obligations convertibles conclu avec ESGO, investisseur américain spécialisé dans la santé | /EIN News/ -- Pixium Vision annonce la résiliation de l’accord de financement par voie d’obligations convertibles conclu avec ESGO, investisseur américain spécialisé dans la santé La résiliation n'entraînera pas de pénalités pour Pixium Vis... |
27.01.2023 | Assemblée Générale Extraordinaire du 15 février 2023 : Modalités de mise à disposition des documents préparatoire | /EIN News/ -- Assemblée Générale Extraordinaire du 15 février 2023 : Modalités de mise à disposition des documents préparatoires
Paris, le 27 janvier 2023 – 18h00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641 - Mnemo: ALPIX),... |
27.01.2023 | Extraordinary General Meeting of February 15, 2023: Notice of publication of the preparatory documents | /EIN News/ -- Extraordinary General Meeting of February 15, 2023: Notice of publication of the preparatory documents
Paris, France, January 27, 2023 – 6.00 pm CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics c... |
20.01.2023 | Pixium Vision convenes an Extraordinary General Meeting of Shareholders on February 15, 2023 | /EIN News/ -- Pixium Vision convenes an Extraordinary General Meeting of Shareholders on February 15, 2023
Paris, France, January 20, 2023 – 19:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that d... |
20.01.2023 | Pixium Vision convoque une assemblée générale extraordinaire des actionnaires le 15 février 2023 | /EIN News/ -- Pixium Vision convoque une assemblée générale extraordinaire des actionnaires le 15 février 2023
Paris, France, 20 janvier 2023 - 19h00 CET- Pixium Vision SA (Euronext Growth Paris - FR0011950641), société de bioélectronique q... |
12.01.2023 | Pixium Vision announces peer-reviewed publications demonstrating the potential of the Next Generation PRIMA implant to restore vision at five times higher resolution than current implant | /EIN News/ -- Pixium Vision announces peer-reviewed publications demonstrating the potential of the Next Generation PRIMA implant to restore vision at five times higher resolution than current implant New implants leverage existing PRIMA de... |
12.01.2023 | Pixium Vision annonce la publication de plusieurs articles démontrant le potentiel de l’implant PRIMA nouvelle génération pour restaurer la vision avec une résolution cinq fois supérieure à celle de l... | /EIN News/ -- Pixium Vision annonce la publication de plusieurs articles démontrant le potentiel de l’implant PRIMA nouvelle génération pour restaurer la vision avec une résolution cinq fois supérieure à celle de l’implant actuel Les nouvea... |
28.12.2022 | Pixium Vision welcomes judgment by Paris Commercial Court against Second Sight Medical Products | /EIN News/ -- Pixium Vision welcomes judgment by Paris Commercial Court against Second Sight Medical Products Court finds Second Sight Medical Products breached 2021 contractual obligations to Pixium Vision Court orders Second Sight Medical... |
28.12.2022 | Pixium Vision accueille favorablement le jugement du Tribunal de commerce de Paris contre Second Sight Medical Products | /EIN News/ -- Pixium Vision accueille favorablement le jugement du Tribunal de commerce de Paris contre Second Sight Medical Products Le Tribunal a conclu que Second Sight Medical Products a violé ses obligations contractuelles envers Pixiu... |
15.12.2022 | Pixium Vision announces completion of implantations in the European pivotal trial PRIMAvera and confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024 | /EIN News/ -- Pixium Vision announces completion of implantations in the European pivotal trial PRIMAvera and confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024 38 patients have been implanted wit... |
15.12.2022 | Pixium Vision annonce avoir finalisé les implantations de son étude pivot européenne PRIMAvera et confirme l’annonce des résultats d’ici à la fin 2023 ainsi que la soumission réglementaire en Europe a... | /EIN News/ -- Pixium Vision annonce avoir finalisé les implantations de son étude pivot européenne PRIMAvera et confirme l’annonce des résultats d’ici à la fin 2023 ainsi que la soumission réglementaire en Europe au premier semestre 2024 38... |
21.10.2022 | Pixium Vision announces its cash position at 30 September 2022 and provides an update on its activities | Pixium Vision announces its cash position at
30 September 2022 and provides an update on its activities
Paris, 21 October 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company tha... |
11.10.2022 | Pixium Vision announces the publication of peer-reviewed clinical data of the Prima System in Dry AMD in the Journal of Neural Engineering | Pixium Vision announces the publication of peer-reviewed clinical data of the Prima System in Dry AMD in the Journal of Neural Engineering Distance between the implant and the target cells was stable over the long-term follow-upNo significa... |
04.10.2022 | Pixium Vision announces participation in investor conferences and events in October 2022 | Pixium Vision announces participation in investor conferences and events in October 2022
Paris, France, October 4, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that devel... |
19.09.2022 | Pixium Vision announces reaching its enrollment target in the European pivotal trial PRIMAvera and implantations planned to be completed by end 2022 | Pixium Vision announces reaching its enrollment target in the European pivotal trial PRIMAvera and implantations planned to be completed by end 2022 The target number of 38 patients have been enrolled at clinical sites in France, Germany, t... |
13.09.2022 | Pixium Vision announces implantation of first patient in Italy in Prima System European pivotal trial PRIMAvera | Pixium Vision announces implantation of first patient in Italy in Prima System European pivotal trial PRIMAvera First patient treated at PRIMAvera clinical site in Rome, ItalyFollows successful implantations at clinical sites in France, Ger... |
13.09.2022 | Pixium Vision announces implantation of first patient in Italy in Prima System European pivotal trial PRIMAvera | Pixium Vision announces implantation of first patient in Italy in Prima System European pivotal trial PRIMAvera First patient treated at PRIMAvera clinical site in Rome, Italy Follows successful implantations at clinical sites in France, Ge... |
06.09.2022 | Pixium Vision announces participation in upcoming investor conferences in September 2022 | Pixium Vision announces participation in upcoming investor conferences in September 2022
Paris, France, September 6, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that dev... |
29.08.2022 | Pixium Vision announces participation in upcoming scientific conferences in September 2022 | Pixium Vision announces participation in upcoming scientific conferences in September 2022
Paris, France, August 29, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that dev... |
11.08.2022 | Pixium Vision to attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022 | Pixium Vision to attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022
Paris, France, August 11, 2022 – 19:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics comp... |
03.08.2022 | Pixium Vision announces regulatory approval of remote rehabilitation system for patients in clinical trials | Pixium Vision announces regulatory approval of remote rehabilitation system for patients in clinical trials Remote rehabilitation approved in France, Germany, Italy, Spain and the NetherlandsFirst feature of new remote patient engagement pl... |
26.07.2022 | Pixium Vision announces successful implantation of first patient in the Netherlands in Prima System European pivotal trial PRIMAvera | Pixium Vision announces successful implantation of first patient in the Netherlands in Prima System European pivotal trial PRIMAvera PRIMAvera clinical site opens at the Rotterdam Eye Hospital in the NetherlandsFollows successful implantati... |
22.07.2022 | Pixium Vision announces its financial results for H1 2022 and provides a business update | Pixium Vision announces its financial results for H1 2022 and provides a business update Cash position at 30 June 2022: €7,2 millionPRIMAvera European pivotal study ongoing and on track to report data around end 2023Post period event: Imple... |
14.07.2022 | Pixium Vision annonce la mise en place d’un financement d’un montant nominal maximum de 30 M€, et le tirage d’une première tranche de 5,5 M€ | Pixium Vision annonce la mise en place d’un financement d’un montant nominal maximum de 30 M€, et le tirage d’une première tranche de 5,5 M€
(Mise en œuvre de la délégation de compétence conférée par la 6ème résolution de l’Assemblée Généra... |
14.07.2022 | Pixium Vision announces the implementation of a financing of a maximum nominal amount of €30 million, and the drawdown of a first tranche of €5.5 million. | Pixium Vision announces the implementation of a financing of a maximum nominal amount of €30 million, and the drawdown of a first tranche of €5.5 million.
Implementation of the delegation of authority granted by the 6th resolution of the Co... |
24.06.2022 | Pixium Vision expands its Board of Directors with the appointment of Anja Krammer and August Moretti | Pixium Vision expands its Board of Directors with the appointment of Anja Krammer and August Moretti
Paris, France, June 24, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company ... |
22.06.2022 | Descriptif du programme de rachat d’actions autorisé par l’Assemblée Générale Mixte du 22 juin 2022 | Communiqué information réglementée
Descriptif du programme de rachat d’actions autorisé par l’Assemblée Générale Mixte du 22 juin 2022
Paris, le 22 juin 2022 – 19h00 CEST – En application des dispositions des articles 241-1 à 241-5 du Règle... |
22.06.2022 | Assemblée Générale Mixte du 22 juin 2022 – Résultats | Assemblée Générale Mixte du 22 juin 2022 –
Résultats
Paris, le 22 juin 2022 – 19h00 CEST – L’Assemblée Générale Mixte des actionnaires de Pixium Vision SA (Euronext Growth Paris - FR0011950641 - Mnemo: ALPIX), société bioélectronique qui dé... |
16.06.2022 | Современные зрительные импланты | Зрительный анализатор – это основной инструмент получения информации об окружающей среде. Зрение для животных – детектор опасности, сигнал о наличии добычи, средство ориентации в пространстве, а для человека – главный способ коммуникации и ... |
28.04.2022 | Results of Combined General Meeting held on April 19, 2022 | Results of Combined General Meeting held on April 19, 2022 Annual General Meeting of Shareholders to be held on June 22, 2022
Paris, France, April 28, 2022 – 07:00 CET – The Combined Shareholders Meeting of Pixium Vision SA (Euronext Growth... |
19.04.2022 | Pixium Vision announces its cash position at 31 March 2022 and provides an update on its activities and financial outlook until the end of 2022 | Pixium Vision announces its cash position at 31 March 2022 and provides an update on its activities and financial outlook until the end of 2022
Paris, France, April 19, 2022 – 07:00 CET– Pixium Vision SA (Euronext Growth Paris - FR001195064... |
04.04.2022 | Combined General Meeting of April 19, 2022: Availability of preparatory documents | Combined General Meeting of April 19, 2022: Availability of preparatory documents
Paris, France, April 4, 2022 – 07:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vi... |
29.03.2022 | Pixium Vision announces FDA approval of clinical trial expansion of Prima System US feasibility study to Stanford Medicine | Pixium Vision announces FDA approval of clinical trial expansion of Prima System US feasibility study to Stanford Medicine FDA approves new additional study location at Stanford Medicine
Paris, France, January 19, 2022 – 07:00 CET– Pixium V... |
24.03.2022 | Pixium Vision to participate in the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest on March 28 - 30 | Pixium Vision to participate in the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest on March 28 - 30
Paris, France, March 24, 2022 – 07:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioe... |
14.03.2022 | Pixium Vision convenes a Combined General Meeting of Shareholders on April 19, 2022 | Pixium Vision convenes a Combined General Meeting of Shareholders on April 19, 2022
Paris, France, March 14, 2022 – 19:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops inn... |
06.01.2022 | Pixium Vision to attend BIOMED EVENT® by Invest Securities on January 26, 2022 | Pixium Vision to attend BIOMED EVENT® by
Invest Securities on January 26, 2022
Paris, France, January 6, 2022 – 07:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vis... |
14.12.2021 | Pixium Vision : to attend 11th Annual LifeSci Partners Corporate Access Event | PRESS RELEASE
Pixium Vision to attend 11th Annual LifeSci Partners
Corporate Access Event
CEO Lloyd Diamond to participate in a panel discussion on "Med Tech / Digital Tools: What's the Mindset for 2022?" - January 5, 2022, at 02:... |
14.12.2021 | Pixium Vision to attend 11th Annual LifeSci Partners Corporate Access Event | Pixium Vision to attend 11th Annual LifeSci Partners Corporate Access Event CEO Lloyd Diamond to participate in a panel discussion on “Med Tech / Digital Tools: What’s the Mindset for 2022?” – January 5, 2022, at 02:00 pm ET / 08:00 pm CET
... |
08.12.2021 | Pixium Vision gaining confidence in execution timeline of the PRIMAvera pivotal trial following first patient implantation in the UK | Pixium Vision gaining confidence in execution timeline of the PRIMAvera pivotal trial following first patient implantation in the UK Successful implantation of the first patient in the PRIMAvera study in the UKFollows successful implantatio... |
08.12.2021 | Pixium Vision gaining confidence in execution timeline of the PRIMAvera pivotal trial following first patient implantation in the UK | Pixium Vision gaining confidence in execution timeline of the PRIMAvera pivotal trial following first patient implantation in the UK Successful implantation of the first patient in the PRIMAvera study in the UKFollows successful implantatio... |
25.11.2021 | Pixium Vision to present at BTIG’s Ophthalmology Day | Pixium Vision to present at BTIG’s Ophthalmology Day
Paris, France, November 25, 2021 – 07.00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable pa... |
08.11.2021 | Pixium Vision to present at the 3rd edition of Investir Day in Paris, November 2021 | Pixium Vision to present at the 3rd edition of Investir Day in Paris, November 2021
Paris, France, 8 November 2021 – 7:00 a.m. CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative b... |
13.10.2021 | Pixium Vision announces positive long-term follow-up scientific data on PRIMA implant from Prima System French feasibility study | Pixium Vision announces positive long-term follow-up scientific data on PRIMA implant from
Prima System French feasibility study PRIMA implant is well tolerated and safe in patients 36 months after implantationImplant is highly stable with ... |
05.10.2021 | Pixium Vision : to attend the 8th Annual Healthtech Investment Forum on October 5 & 6, 2021 | PRESS RELEASE
Pixium Vision to attend the 8th Annual Healthtech
investment forum on October 5 & 6, 2021
Paris, France, October 4, 2021 - 18.00 CET- Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that d... |
08.09.2021 | Pixium Vision : expands collaboration with Stanford University on next generation Prima System implants | Pixium Vision expands collaboration with Stanford University on next generation Prima System implants New implants to leverage existing PRIMA design and significantly improve implant resolutionCollaboration expands existing agreement betwee... |
13.08.2021 | Pixium Vision : Geographical expansion of PRIMAvera European pivotal study with opening of first UK clinical site at Moorfields Eye Hospital | PRESS RELEASE
Pixium Vision announces geographical expansion of PRIMAvera European pivotal study with opening of first UK clinical site at Moorfields Eye Hospital
London's Moorfields Eye Hospital is the premiere ophthalmology center in the ... |
13.08.2021 | Pixium Vision announces geographical expansion of PRIMAvera European pivotal study with opening of first UK clinical site at Moorfields Eye Hospital | Pixium Vision announces geographical expansion of PRIMAvera European pivotal study with opening of
first UK clinical site at Moorfields Eye Hospital London’s Moorfields Eye Hospital is the premiere ophthalmology center in the UKPRIMAvera st... |
27.07.2021 | Pixium Vision : announces its financial results for H1 2021 and provides a business update | PRESS RELEASE
Pixium Vision announces its financial results for H1 2021 and provides a business update Cash position at 30 June 2021: €10.1 million
PRIMAvera European pivotal study of Prima System ongoing
Pixium Vision appointed Offer Nonho... |
13.07.2021 | Pixium Vision : announces a capital increase of approximately 8 million through a private placement | Pixium Vision announces a capital increase of approximately €8 million through a private placement
Paris, France, July 13 2021 – 11:00 a.m. CET - Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX) (“Pixium Vision” or the “Company”... |
25.06.2021 | Pixium Vision appoints experienced international financial executive Offer Nonhoff as CFO | Pixium Vision appoints experienced international financial executive Offer Nonhoff as CFO
Paris, France, June 25 2021 – 07.00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bi... |
02.06.2021 | Pixium Vision announces business update and key upcoming milestones to deliver on its business plan | Pixium Vision announces business update and key upcoming milestones to deliver on its business plan 1st patient successful implant activation in PRIMAvera pivotal EU studyOn track to report PRIMAvera data in early 2023 and submit CE mark in... |
21.05.2021 | Heru sets sights on virtual reality eye tests and therapies with $30M round | The classic eye chart wall poster is getting an upgrade, with newcomer Heru looking to bring vision tests into virtual reality.
Using commercially available headsets, the company is developing an artificial-intelligence-powered diagnostic t... |
23.04.2021 | PIXIUM VISION
Pixium Vision : receives HealthTech Award for Prima System at the MedTech Forum | PRESS RELEASE
Pixium Vision receives HealthTech Award for Prima System at the MedTech Forum
Paris, France, April 21, 2021 - 07.00 CET- Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovativ... |
21.04.2021 | PIXIUM VISION
Pixium Vision : receives HealthTech Award for Prima System at the MedTech Forum | Pixium Vision receives HealthTech Award
for Prima System at the MedTech Forum
Paris, France, April 21, 2021 – 18.00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic visio... |
19.04.2021 | PIXIUM VISION
Pixium Vision : announces its cash position at 31 March 2021 and provides an update on its activities and financial outlook until the end of 2021 | PRESS RELEASE
Pixium Vision announces its cash position at 31 March 2021 and provides an update on its activities and financial outlook until the end of 2021.
Paris, 16 April 2021 - 6:00 p.m. CEST - Pixium Vision (Euronext Growth Paris - FR... |
19.04.2021 | PIXIUM VISION
Pixium Vision : announces the drawdown of a further tranche, with a nominal value of 1.5 million, under the financing contract with ESGO | Pixium Vision announces the drawdown of a further tranche, with a nominal value of €1.5 million, under the financing contract with ESGO
Paris, 19 April 2021 – 8.00 p.m. CET – Pixium Vision (FR0011950641 - ALPIX), a bioelectronics company th... |
18.04.2021 | PIXIUM VISION
Pixium Vision : announces its cash position at 31 March 2021 and provides an update on its activities and financial outlook until the end of 2021. | Pixium Vision announces its cash position at 31 March 2021 and provides an update on its activities and financial outlook until the end of 2021.
Paris, 16 April 2021 – 6:00 p.m. CEST - Pixium Vision (Euronext Growth Paris - FR0011950641 - A... |
30.03.2021 | Pixium Vision announces new compelling results with Prima System demonstrating integration of prosthetic and natural vision | Data mark a major step forward in treatment of atrophic AMD
Results confirm the safety and stability of the Prima System implant over 24-30 months follow-up
Prima System pivotal PRIMAvera study ongoing
Paris, France, March 30 2021 - CET– Pi... |
09.03.2021 | Continuation of the business combination project between Pixium Vision et Second Sight Medical Products | Paris, France, March 09, 2021 – Pixium Vision (Euronext Growth Paris - FR0011950641) announces that the business combination with Second Sight Medical Products, Inc. (« Second Sight ») (Nasdaq: EYES) continues under the terms announced to t... |
09.03.2021 | Poursuite du projet de rapprochement entre Pixium Vision et Second Sight Medical Products Inc. | Poursuite du projet de rapprochement entre Pixium Vision et Second Sight Medical Products Inc.
Paris, France, le 9 mars 2021 8h30 – Pixium Vision (Euronext Growth Paris - FR0011950641) indique poursuivre son opération de rapprochement avec ... |
09.03.2021 | PIXIUM VISION
Pixium Vision : Continuation of the business combination project between Pixium Vision et Second Sight Medical Products | Paris, France, March 09, 2021 – Pixium Vision (Euronext Growth Paris - FR0011950641) announces that the business combination with Second Sight Medical Products, Inc. (« Second Sight ») (Nasdaq: EYES) continues under the terms announced to t... |
09.03.2021 | PIXIUM VISION
Pixium Vision : Continuation of the business combination project between Pixium Vision and Second Sight Medical Products | Continuation of the business combination project between Pixium
Vision and Second Sight Medical Products
Paris, France, March 09, 2021 - Pixium Vision (Euronext Growth Paris - FR0011950641) announces that the business combination with Secon... |
06.01.2021 | Pixium Vision : and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market | Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market
Aims to create a global leader with potential to treat nearly all forms of blindness
Combined company to... |
06.01.2021 | PIXIUM VISION
Pixium Vision : and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market | Pixium Vision and Second Sight Medical Products announce business combination, creating a global leader in the sight restoration market
Aims to create a global leader with potential to treat nearly all forms of blindness
Combined company to... |
04.12.2020 | PIXIUM VISION
Pixium Vision : Edison Research augmente sa valorisation à 134,0 M sur la base de l'approbation de l'étude PRIMAvera | Pixium Vision
ANSM approval to start PRIMAvera pivotal study
Pixium Vision announced on 20 November that it has received approval from the French regulatory health authority, ANSM, to start its PRIMAvera European pivotal study of its Prima ... |
04.12.2020 | Pixium Vision : Edison Research augmente sa valorisation à 134,0 M sur la base de l'approbation de l'étude PRIMAvera | Pixium Vision
ANSM approval to start PRIMAvera pivotal study
Pixium Vision announced on 20 November that it has received approval from the French regulatory health authority, ANSM, to start its PRIMAvera European pivotal study of its Prima ... |
23.07.2020 | PIXIUM VISION
Pixium Vision : announces its financial results as of June 30 2020 and provides business update | Pixium Vision announces its financial results
as of June 30 2020 and provides business update
Paris, July 23rd 2020 - 6.00 p.m. CET – Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX), a company that develops innovative bionic vi... |
06.07.2020 | PIXIUM VISION
Success of the capital increase with pre-emptive subscription rights: 7.3 million raised to finance the Prima System PRIMAvera pivotal study | Success of the capital increase with pre-emptive subscription rights:
€7.3 million raised to finance the Prima System PRIMAvera pivotal study
Paris, 6 July 2020 – 7.00 a.m. CET - Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX) ... |
26.11.2013 | Funding: French retinal implant maker Pixium Vision raises $20M | Retinal implants maker Pixium landed a $20.3 million (€15 million) Series A funding round, planning to use the funds to further develop its IRIS "bionic eye" technology.
The IRIS system is comprised of a retinal implant and a pair... |
25.11.2013 | Pixium Vision Raises €15M in Series A Financing | Pixium Vision, a Paris, France-based developer of innovative retinal implant systems, closed a €15m Series A extension financing.
The round was led by Sofinnova Partners, with participation from Bpifrance, through the InnoBio fund, and exis... |
- | Pixium Vision : Continuation of the business combination project between Pixium Vision et Second Sight Medical Products | Paris, France, March 09, 2021 – Pixium Vision (Euronext Growth Paris - FR0011950641) announces that the business combination with Second Sight Medical Products, Inc. (« Second Sight ») (Nasdaq: EYES) continues under the terms announced to t... |
- | Pixium Vision : Continuation of the business combination project between Pixium Vision and Second Sight Medical Products | Continuation of the business combination project between Pixium
Vision and Second Sight Medical Products
Paris, France, March 09, 2021 - Pixium Vision (Euronext Growth Paris - FR0011950641) announces that the business combination with Secon... |